

Kevin H Eng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/304274/publications.pdf>

Version: 2024-02-01

55
papers

1,991
citations

304743

22
h-index

276875

41
g-index

57
all docs

57
docs citations

57
times ranked

4567
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers. <i>Cancers</i> , 2022, 14, 731.	3.7	2
2	Estrogen Receptor-Beta2 (ER β 2)â€“Mutant p53â€“FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). <i>Cancers</i> , 2022, 14, 1120.	3.7	13
3	VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2355-2369.	4.2	5
4	Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 790-810.	3.4	29
5	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. <i>Communications Biology</i> , 2021, 4, 862.	4.4	5
6	Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment.. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 416-434.	0.4	0
7	Wholeâ€“exome sequencing of ovarian cancer families uncovers putative predisposition genes. <i>International Journal of Cancer</i> , 2020, 146, 2147-2155.	5.1	12
8	USP1 Regulates TAZ Protein Stability Through Ubiquitin Modifications in Breast Cancer. <i>Cancers</i> , 2020, 12, 3090.	3.7	30
9	Transmission of X-linked Ovarian Cancer: Characterization and Implications. <i>Diagnostics</i> , 2020, 10, 90.	2.6	5
10	Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells. <i>Leukemia</i> , 2020, 34, 2460-2472.	7.2	7
11	Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. <i>Genome Research</i> , 2020, 30, 347-360.	5.5	47
12	Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 71-81.	7.0	109
13	Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils. <i>Cancer Immunology Research</i> , 2020, 8, 819-828.	3.4	25
14	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2669-2683.	1.8	14
15	In situ thermal ablation augments antitumor efficacy of adoptive T cell therapy. <i>International Journal of Hyperthermia</i> , 2019, 36, 22-36.	2.5	14
16	Active and secondhand smoke exposure throughout life and DNA methylation in breast tumors. <i>Cancer Causes and Control</i> , 2019, 30, 53-62.	1.8	10
17	Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2019, 120, 207-217.	6.4	62
18	Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. <i>JCI Insight</i> , 2019, 4, .	5.0	93

#	ARTICLE	IF	CITATIONS
19	Lifetime physical inactivity is associated with lung cancer risk and mortality. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 37-45.	1.7	15
20	Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors. <i>Environmental Research</i> , 2018, 161, 418-424.	7.5	31
21	Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1028-1035.	2.9	172
22	Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer. <i>PLoS ONE</i> , 2018, 13, e0206913.	2.5	9
23	Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. <i>PLoS Genetics</i> , 2018, 14, e1007194.	3.5	15
24	Transcriptional changes associated with growth of muscle-invasive bladder cancer cell lines in nude mice. <i>American Journal of Clinical and Experimental Urology</i> , 2018, 6, 138-148.	0.4	5
25	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. <i>Oncolimmunology</i> , 2017, 6, e1264563.	4.6	23
26	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 420-425.	1.4	61
27	Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 52-57.	1.4	12
28	Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. <i>Gynecologic Oncology</i> , 2017, 146, 491-497.	1.4	53
29	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
30	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. <i>Cancer Causes and Control</i> , 2017, 28, 469-486.	1.8	28
31	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. <i>British Journal of Cancer</i> , 2017, 117, 1063-1069.	6.4	16
32	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	7.0	87
33	Evaluation of satisfaction with work-life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study. <i>Gynecologic Oncology Reports</i> , 2016, 16, 17-20.	0.6	8
34	HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 158-162.	1.4	8
35	DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study. <i>Epigenetics</i> , 2016, 11, 643-652.	2.7	17
36	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2016, 115, 95-101.	6.4	39

#	ARTICLE	IF	CITATIONS
37	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5
38	PRAME expression and promoter hypomethylation in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 45352-45369.	1.8	72
39	On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. <i>Oncotarget</i> , 2015, 6, 36308-36318.	1.8	71
40	Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor- β and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 352-357.	1.4	70
41	TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2015, 138, 159-164.	1.4	21
42	Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 139, 228-235.	1.4	26
43	Immuno-stimulatory/regulatory gene expression patterns in advanced ovarian cancer. <i>Genes and Cancer</i> , 2015, 6, 399-407.	1.9	4
44	Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. <i>Oncotarget</i> , 2015, 6, 18641-18652.	1.8	20
45	Connecting Prognostic Ligand Receptor Signaling Loops in Advanced Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e107193.	2.5	5
46	Differential Requirement for Src Family Tyrosine Kinases in the Initiation, Progression, and Metastasis of Prostate Cancer. <i>Molecular Cancer Research</i> , 2014, 12, 1470-1479.	3.4	22
47	Randomized reverse marker strategy design for prospective biomarker validation. <i>Statistics in Medicine</i> , 2014, 33, 3089-3099.	1.6	12
48	Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E672-81.	7.1	72
49	Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e104099.	2.5	65
50	Differential Antigen Expression Profile Predicts Immunoreactive Subset of Advanced Ovarian Cancers. <i>PLoS ONE</i> , 2014, 9, e111586.	2.5	10
51	Src controls castration recurrence of CWR22 prostate cancer xenografts. <i>Cancer Medicine</i> , 2013, 2, 784-792.	2.8	11
52	Transient Genotype-by-Environment Interactions Following Environmental Shock Provide a Source of Expression Variation for Essential Genes. <i>Genetics</i> , 2010, 184, 587-593.	2.9	18
53	Finding Jumps in Otherwise Smooth Curves: Identifying Critical Events in Political Processes. <i>Political Analysis</i> , 2010, 18, 57-77.	3.3	5
54	A Phylogenetic Mixture Model for the Evolution of Gene Expression. <i>Molecular Biology and Evolution</i> , 2009, 26, 2363-2372.	8.9	13

#	ARTICLE	IF	CITATIONS
55	Statistical Tests for Clonality. Biometrics, 2007, 63, 522-530.	1.4	31